Skip to content

Novo Nordisk bets China demand will offset government price cuts

June 28, 2017

Danish pharmaceutical company Novo Nordisk A/S (NVO, NOVO.B-KO) is betting that wider uptake of its products in China will offset price reductions required by the Chinese government. Regulators in the country are expected to decide soon whether to include two of Novo Nordisk’s newer medications–Victoza, used to treat Type 2 diabetes, and NovoSeven, a hemophilia treatment–on the country’s drug reimbursement list. The state-funded program reimburses Chinese patients part or all of the drug’s price, depending on its classification. Both drugs are currently available for sale in China, but patients must pay in full for the medicines. ADRs closed down 2% at $43.50.


From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: